November 9–10, 2021
Virtual Conference

Scientific program

Program – Tuesday, November 9, 2021

9:00–10:30 am

Live Session I

CAR T cells for cancer therapy
Keynote: Rössig, Claudia (Münster University Hospital (UKM), Münster, Germany)

Cell based therapy in hematology
Keynote: Ciceri, Fabio (IRCCS Ospedale San Raffaele, Milan, Italy)

10:30–11:00 am


11:00 am – 12:00 pm

Poster Session I – Improving the efficacy and safety profile of cell therapies  |  Biomarkers and immuno monitoring

Poster authors (group 1) are available for live chat.

Low energy electron-based inactivation of ErbB2/HER2-directed CAR-NK-92 cells for GBM therapy
Kistenmacher, Ann-Kathrin

Transient expression of a CD123-directed chimeric antigen receptor for safe immunotherapy of acute myeloid leukemia
Kitte, Reni

Dysregulation of DNA damage repair signalling upon LEDGF knockout
Liedtke, Victoria

Acute ischemic stroke, dyspnoea, thromboses in multiple arteries and abdominal pain: An unorthodox and rare presentation of multiple myeloma
Navandar, Raghav

 A time-resolved meta-analysis of consensus gene expression profiles during human T-cell activation
Rade, Michael

 An inflammatory-related plasma protein profiling in Barrett’s carcinoma patients
Thieme, René

12:00–12:30 pm


12:30-1:15 pm

Industry Sponsered Session

Supported by Gilead

DLBCL: CAR-T data and clinical experience
Glaß, Bertram (Helios Clinic Berlin-Buch, Berlin, Germany)

CAR-T cell therapy in Germany: Clinical experience and status quo
Vucinic, Vladan (University of Leipzig Medical Center, Leipzig, Germany)

MCL: CAR-T data and clinical experience
Heß, Georg (University Medical Center Mainz, Mainz, Germany)

1:15-1:20 pm


1:20-1:45 pm

Industry Flash Talk – Novel immunotherapeutic approaches in multiple myeloma and solid tumors

Supported by GlaxoSmithKline

Introduction and Belantamab mafodotin trials
Merz, Maximilian (University of Leipzig Medical Center, Leipzig, Germany)

Targeting NY-ESO-1 for personalized cancer immunotherapy
Schmitt, Michael (Heidelberg University Hospital, Heidelberg, Germany)

Discussion and closure
Merz, Maximilian (University of Leipzig Medical Center, Leipzig, Germany)

1:45-2:15 pm


2:15-3:45 pm

Live Session II

From CARs to TRUCKs: the 4th generation of CAR T cells
Keynote: Abken, Hinrich (RCI – University of Regensburg, Regensburg, Germany)

Beyond CD19 – CAR-T cells targeting solid tumors
Keynote: Cathomen, Toni (Medical Center – University of Freiburg, Freiburg, Germany)

3:45-4:15 pm


4:15-5:15 pm

Poster Session II – Cell-based therapy in oncology  |  Cell-based therapy in hematology  |  Cancer vaccines and vector-based therapy

Poster authors (group 2) are available for live chat.

Bringing automation to large scale manufacturing of gene-modified T cells for adoptive cell therapy
Barth, Carola

Development of a 3D head and neck cancer cell culture model for the assessment of NK cell based therapies
Ciulean, Sonya

Production of superior RNA CAR T cells using a novel lipid nanoparticle delivery platform
Rabel, Martin

Allogeneic hematopoietic stem cell transplantation (HSCT) in patients (pts) with adult onset leukoencephalopathy with axonal spheroids (ALSP)
Franke, Georg-Nikolaus

Deciphering the role of HLA-DO in immune responses after allogeneic stem cell transplantation
Zeun, Julia

TheraVision – Platform technology for the development, production and testing of oncolytic viruses
Bailer, Susanne



Program – Wednesday, November 10, 2021

9:00-10:30 am

Live Session III

Cellular therapy for the treatment of solid cancers
Keynote: Haanen, John (The Netherlands Cancer Institute, Amsterdam, The Netherlands)

Combining cell therapy and immune checkpoint inhibitors
Keynote: Chabannon, Christian (Institut Paoli-Calmettes, Marseille, France)

10:30-11:00 am


11:00 am - 12:00 pm

Poster Session III –Tumor microenvironment  |  Precision medicine addressing tolerance and inflammation

Poster authors (group 3) are available for live chat.

Inhibition of the pentose-phosphate-pathway (PPP) mediates macrophage reprogramming and induces increased antibody-dependent lymphoma cell clearance by macrophages while supportive bystander function is diminished
Beielstein, Anna

The role of tumor microenvironment and immune pathogenesis in breast cancer initiation, progression, invasion and metastasis
López, David

Modulation of cystatin F activation or glycosylation impacts the function of NK cells
Senjor, Emanuela

Extracellular components of the myelodysplastic stromal bone marrow microenvironment as potential therapeutic target
Wobus, Manja

Distinct patterns of sterile inflammation in the bone marrow of LR-MDS patients
Rolfs, Clara

12:00 –12:30 pm


12:30-1:15 pm

Industry Sponsered Session – 3 Immuno-Swords fighting cancer: Inhibition of Pro-Tumor Inflammation, TIM-3-Inhibition and CAR-T-cells

Supported by Novartis

Pro-Tumor Inflammation (PTI) - a new target for fighting cancer. First findings in NSCLC.
Kobold, Sebastian (University Hospital of Munich (LMU), Munich, Germany)

Immune targeted approaches in myeloid neoplasms and lymphoma
Platzbecker, Uwe (University of Leipzig Medical Center, Leipzig, Germany)

1:15–1:20 pm


1:20–2:05 pm

Industry Sponsered Session – New therapy approaches in hematology and immunooncology

Supported by Bristol Myers Squibb

CAR-T-cell therapies for multiple myeloma
Kortüm, Martin (University Hospital Würzburg, Würzburg, Germany)

State oft the art therapy – Immunooncology in 2021 – What is new?
Ivanyi, Philipp (MHH, Hannover, Germany)

Discussion of all speakers

2:05–2:15 pm


2:15–3:45 pm

Live Session IV

Genomic biomarkers of immunotherapy response and monitoring
Keynote: Dienstmann, Rodrigo (Vall d'Hebron Institute of Oncology, Barcelona, Spain)

Precision medicine addressing tolerance and inflammation
Keynote: Kordasti, Shahram (Kings College London, London, UK)

3:45-4:15 pm


4:15-5:00 pm

Industry Sponsered Session

Supported by Amgen

T cell engaging therapies: Blinatumomab and beyond
Bargou, Ralf C. (University Hospital Würzburg, Würzburg, Germany)
Klinger, Matthias (Amgen Research (Munich) GmbH, Munich, Germany)